| 证券代码 | SGYP.O |
| 证券名称 | Synergy Pharmaceuticals Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 2011-12-01 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Synergy Pharmaceuticals, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 420 Lexington Avenue, Suite 2012, New York, New York, USA |
| 成立日期 | 1992-09-11 |
| 董事会主席 | Melvin K. Spigelman |
| 公司属地 | United States 美国 |
| 公司网址 | www.synergypharma.com |
| 电话 | +1 (212) 297-0020 |
| 传真 | +1 (212) 297-0019 |
| 公司简介 | Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of GI diseases and disorders. Synergy’s proprietary GI platform includes one commercial product TRULANCE(plecanatide) and a second product candidate - dolcanatide. |